Eli Lilly Licenses Eva Pharma to Produce Rheumatoid Arthritis Drug in Egypt

On 4 September 2024, US pharma Eli Lilly announced that it has licensed to Eva Pharma to manufacture its drug for rheumatoid arthritis in Egypt. Under the agreement, Eva Pharma will manufacture the drug Olumiant and will hold the distribution rights to 49 countries across Africa.

Olumiant is a medicine used to treat an autoimmune disfunction called alopecia areata which causes rheumatoid arthritis and hair loss. In 2023, Eli Lily registered $922.6 million in sales of Olumiant.

Since 2021, Lily and Eva have partnered to produce insulin in Egypt. With this new agreement, both parties seek to expand the partnership and replicate the success on the African market.